These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21535327)

  • 1. Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2012 Jan; 18(1):94-101. PubMed ID: 21535327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
    Shinkoda Y; Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Takedani H; Kawasugi K; Taki M; Matsushita T; Tawa A; Nogami K; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Uchiba M; Kawakami K; Sameshima K; Ohashi Y; Saito H
    Haemophilia; 2017 Jan; 23(1):59-66. PubMed ID: 27480904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, distribution, and excretion of 125I-labeled human plasma-derived-FVIIa and -FX with MC710 (FVIIa/FX mixture) in rats.
    Nakatomi Y; Tsuji M; Nakashima T; Gokudan S; Miyazaki H; Tomokiyo K; Ogata Y; Harano S; Matsui H; Shigaki T; Nakamura T; Mogi M
    Thromb Res; 2012 Jan; 129(1):62-7. PubMed ID: 21621824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma-derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors.
    Sakai M; Amano K; Chin M; Takedani H; Ishida H; Sakashita K; Taki M; Migita M; Watanabe H; Ishimura M; Nogami K; Harano S; Shirahata A
    Haemophilia; 2023 Mar; 29(2):456-465. PubMed ID: 36516312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
    Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
    Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma-derived factors VIIa and X mixtures (Byclot
    Ochi S; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
    Nakatomi Y; Nakashima T; Gokudan S; Miyazaki H; Tsuji M; Hanada-Dateki T; Araki T; Tomokiyo K; Hamamoto T; Ogata Y
    Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model.
    Hedner U; Ljundberg J; Lund-Hansen T
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):145-51. PubMed ID: 2130926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
    Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
    Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
    Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.
    Shirayama R; Takedani H; Chikasawa Y; Ishiguro A; Ishimura M; Isobe K; Uchiba M; Ogata Y; Kakuda H; Kusuhara K; Shirahata A
    Blood Coagul Fibrinolysis; 2019 Dec; 30(8):385-392. PubMed ID: 31738288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial.
    Kenet G; Stenmo CB; Blemings A; Wegert W; Goudemand J; Krause M; Schramm W; Kirchmaier C; Martinowitz U
    Thromb Haemost; 2010 Feb; 103(2):351-9. PubMed ID: 20024491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
    Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
    J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.